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Introduction
Hyper-activated or deviated immune responses can result in immunopathological diseases. Paradoxically, immunodeficiency is a frequent cause of such immune-mediated pathologies. This is illustrated for example in patients with common variable immunodeficiency (CVID) who often present with immunopatholo-an immunodeficiency model and LCMV as an infectious trigger. We demonstrate that B cell-deficiency leads to a rapid and fatal CD8 + T cell-mediated immunopathology after infection with the LCMV strain Docile. Importantly, we were able to prevent this immunopathology by strengthening antiviral immunity.
Results and discussion

Fatal CD8 + T cell-mediated immunopathology in B cell-deficient mice after LCMV Docile infection
Inoculation of wild-type (WT) C57BL/6 (B6) mice with a low dose (200 pfu) of LCMV strain Docile induces an acute infection with virus elimination within 2-3 weeks post infection (p.i.) [4] . Importantly, WT mice did not show clinical symptoms after this infection and developed only a transient, small (ß5%) decrease in body weight (BW). In striking contrast, B cell-deficient J H T mice (henceforth referred to as B −/− mice) rapidly lost weight and almost all of them died or had to be euthanized due to their moribund conditions at day 8-10 p.i. (Fig. 1A) . Since LCMV is a non-cytopathic virus, the disease in B −/− mice was likely to be caused by the induced immune response. Indeed, antibody (Ab)-mediated depletion of CD8 + T cells in B −/− mice prevented death in 8 out of 9 mice as well as significant weight loss. Depletion of CD4 + T cells alone had no beneficial effect on survival but when combined with anti-CD8 Ab treatment, it decreased BW loss in comparison to the anti-CD8 Ab-treated group (Fig. 1B ). Of note, T cell-depleted B −/− mice exhibited high viral titers at the end of the observation period (day 21 p.i.) (Supporting Information Fig. 1 ). This further supports the notion that T cells but not the virus itself were responsible for the observed lethal pathology in B −/− mice. In sum, these data show that the LCMV Docile infection induced a rapid and fatal CD8 + T cell-mediated immunopathological disease in mice lacking B cells.
Prolonged antigen presentation and vascular leakage in B −/− mice after LCMV Docile infection
To characterize the disease in LCMV-infected B −/− mice, we first measured the LCMV-specific CD8 + T cell response in spleen, liver and lungs by MHC class I tetramer (gp33-tet) and intracellular IFN-γ staining at day 9 p.i. Functional LCMV-specific CD8 + T cells were detected in B −/− mice but their absolute numbers were somewhat lower than in WT mice (Fig. 1C ). In addition, we observed decreased KLRG1 expression in CD8 + T cell from LCMV-infected B −/− mice when compared to WT mice (Supporting Information Fig. 2 ). Next, we assessed the amount of infectious virus in various organs by focus forming assay ( Fig. 2A) . At day 9 p.i. infectious viral particles were slightly more numerous in spleen, liver, lungs and kidneys of B −/− mice when compared to WT mice; in serum, B −/− mice had ß10-fold higher levels of virus than WT mice. Viral protein as determined by immunohistology of liver and lungs was also more abundant in B −/− mice than in WT mice (Fig. 2B ).
In addition, antigen presenting cells (APC) isolated ex vivo from lungs of LCMV-infected B −/− but not those isolated from infected WT mice were able to stimulate LCMV-specific P14 T cell receptor (TCR) transgenic (tg) CD8 + T cells (Fig. 2C ).
In the LCMV clone 13 chronic infection model, infected vascular endothelial cells have been shown to serve as target cells for LCMV-specific cytotoxic T lymphocytes (CTL). In this model, PD-1-deficiency led to enhanced killing of infected endothelial cells by virus-specific CTL followed by systemic vascular leakage and collapse of the circulatory system [5] . Interestingly, most of the lung endothelial cells (CD45 − CD31 + ) from LCMV-infected B −/− mice were infected with LCMV as deduced from the strong intracellular staining with a LCMV nucleoprotein (NP)-specific mAb (Fig. 2D) mice are unable to produce antibodies and rapidly generated, nonneutralizing LCMV-specific Ab have been shown to speed up virus elimination [4, 8, 9] . Secondly, B cell-deficient mice lack a normal splenic marginal zone [10] which leads to faster spread of virus to peripheral organs [11] . Thirdly, the lack of the splenic marginal zone also results in an impaired type I interferon production [12] . B −/− mice do not develop immunopathological disease after infection with the LCMV strains Armstrong and WE [13, 14] . These viral strains exhibit lower replication speed when compared to the Docile strain, indicating that high antigen load and/or fast spreading of the virus to peripheral organs was required for the development of immunopathological disease. However, infection of WT mice with a high dose (2 × 10 6 pfu) of LCMV Docile which results in high viral titers does not trigger fatal disease ( [15] and Supporting Information Fig. 3 ). Furthermore, B cell receptortransgenic MD4 mice specific for hen egg lysozyme which are also unable to contain a LCMV Docile infection did not develop disease (Supporting Information Fig. 4 ). Thus, lack of B cells appeared to be crucial for the morbidity after LCMV Docile infection. At an early time point (day 4) of infection, B −/− mice exhibited significantly lower viral titers in spleen but increased titers in liver and lungs when compared to WT mice (Supporting Information Fig. 5 ). Hence, it is possible that due to initially low viral load in spleen, exhaustive T cell differentiation is impaired or delayed in B www.eji-journal.eu 
Prevention of LCMV-induced immunopathology in B −/− mice by enhancing immunity
Our data so far indicated that B −/− mice rapidly develop a fatal CD8 + T cell-mediated immunopathological disease after LCMV Docile infection due to concurrent presence of functional LCMVspecific CD8 + T cells and target cells expressing LCMV antigens.
We thus hypothesized that enhancing LCMV-specific CD8 + T cell immunity may prevent CD8 + T cell-mediated immunopathology by reducing the number of infected cells in the body. To test this idea, we vaccinated B −/− mice with a replication-deficient LCMV strain (rLCMV/WEGP Glc6,9) three weeks prior to challenge with LCMV Docile. Indeed, all (7/7) vaccinated B −/− mice survived the LCMV Docile infection whereas all non-vaccinated mice (7/7) died or had to be euthanized due to their moribund condition (Fig. 3A) . Moreover, increasing the precursor frequency of LCMV-specific CD8 + T cells in B −/− mice by adoptive transfer of LCMV-specific P14 TCR tg CD8 + T cells (5 × 10 5 ) from uninfected donor mice also had a protective effect in 4 out 6 B −/− mice (Fig. 3B) .
The absence of a LCMV-specific Ab response in B −/− mice likely contributes to the impaired viral control in these mice. Therefore, we also examined whether passive immunizations with LCMVspecific Ab were able to mitigate disease development. We first tested the virus-neutralizing LCMV glycoprotein (GP)-specific mAb KL25 that was injected 4 days after infection to allow for initial virus replication. The experiments revealed that KL25 mAb treatment protected all (7/7) B −/− mice from death after LCMV Docile infection (Fig. 3C ). In addition, we also used a non-neutralizing LCMV NP-specific mAb (VL4, treatment day 1 p.i.), since we had shown previously that also non-neutralizing LCMV NP-specific Ab were able to enhance CD8 + T cell-mediated viral control in WT mice [4] . Strikingly, treatment of LCMV Docile-infected B −/− mice with VL4 mAb at day 1 p.i. protected 6 out of 7 mice from immunopathology (Fig. 3D) . Vaccination or Ab-treatment of LCMV-infected B −/− mice led to strongly reduced viral load at the end of the observation period (Supporting Information Fig. 7) . Moreover, P14 TCR tg T cell transfer or Ab-treatment prevented high viral load and infection of lung endothelial cells already at day 9 p.i., the time point of disease development in infected nontreated B −/− mice (Supporting Information Fig. 8 ). These findings fit well to our concept that enhancing anti-LCMV immunity in B −/− mice decreases target cell structures for CD8 + T cells and thereby prevents LCMV-induced immunopathology.
Concluding remarks
The growing awareness that immunodeficiency can be the underlying cause of immunopathology requires a rethinking of the therapeutic strategies commonly used to treat such diseases.
Here, we provide a proof-of-concept that immunopathology that is due to impaired immunity in the context of a viral infection, can be prevented by enhancing immunity. Immunopathology in B −/− mice after LCMV Docile infection is caused by a functional antiviral CTL response and the concurrent presence of a high number of infected cells. When we enhanced immunity by active or passive immunization strategies, this did not aggravate the immunopathological processes. In contrast, it reduced antigen load and prevented immune-mediated disease. Interestingly, treatment of LCMV Docile-infected B −/− mice with non-neutralizing LCMV nucleoprotein (NP)-specific Ab was also found to be effective. This finding is well in line with our previous data demonstrating the LCMV NP-specific Ab are capable of speeding up LCMV elimination in WT mice independently of complement and Fcγ receptors [4] . In conclusion, the present study encourages further attempts to evaluate the concept of enhancing immunity to prevent immunopathology also in other settings.
Materials and methods
Mice
C57BL/6NRj mice were purchased from Janvier (Le Genest St-Isle, France). B cell-deficient J H T mice (B6.129P2-Igh-J tm1Cgn /J) [16] and their transgene-negative littermates that were used as WT controls in some experiments and P14 TCR-tg mice (B6;D2-Tg(TcrLCMV)318Sdz/JDvsJ) [17] were bred locally. Mice were housed under specific pathogen-free conditions. Animal care and use was approved by the Regierungspräsidium Freiburg. All experiments were performed according to the german law for animal protection.
Viral infections
Mice were infected intravenously (i.v.) with 200 pfu LCMV strain Docile unless stated otherwise. LCMV was propagated on Madin Darby canine kidney (MDCK) cells. Viral titers were determined by focus-forming assay [18] . For active immunization, mice were injected i.v. with 8 × 10 4 pfu of replication-deficient rLCMV/WEGP Glc6,9 carrying a modified glycoprotein [19, 20] three weeks before challenge infection with LCMV Docile.
Antibody treatments
T cell depletion in vivo was performed by intraperitoneal (i.p.) injection of 200 μg purified anti-CD4 (clone YTS191, BioXcell) and/or anti-CD8 (clone YTS169, BioXcell) mAb at day 3 and day 1 before LCMV infection. For passive immunization, mice received 1 mg purified LCMV GP-specific mAb KL25 [21] (own production) at day 4 p.i. or 500 μg purified LCMV NP-specific mAb (clone VL4, BioXcell) at day 1 p.i. via the intraperitoneal route.
Flow cytometry
Flow cytometry was performed according to the guidelines as published by Cossarizza et al. [22] . Single-cell suspensions of lymphocytes were prepared from spleens by meshing through a metal strainer with a syringe plunger. Lymphocytes from liver were isolated by digestion with Collagenase D (1 mg ml −1 , Roche) and DNaseI (0.1 mg ml −1 , Sigma) followed by meshing the tissue through cell strainers (Greiner) and purification using Percoll gradient (Sigma). Lungs were digested using Collagenase II (140 U ml 
In vitro P14 T cell stimulation assay
Leukocytes from collagenase-and DNase-digested lungs (see above) were isolated by pressing through cell strainers. Suspensions were depleted of B and T cells by staining with PE-conjugated anti-Thy1.2 (clone 53-2.1, eBioscience) and anti-B220 (clone RA3-6B2, eBioscience) Ab, followed by magnetic separation with anti-PE MicroBeads (Miltenyi) according to the manufacturer's instructions. The resulting cells (>80% CD45 + ) were co-cultured at a 1:1 ratio with 1 × 10 5 CFSE-labeled enriched (mouse CD3 T cell isolation kit, BioLegend) P14 CD8 + T cells in 96-well cell culture plates (Thermo Fisher) for 3 days. Afterwards, cell division of P14 T cells identified by the allelic Thy1.1 marker was analyzed by CFSE dye dilution.
Immunohistology
Livers and lungs were fixed in 4% formaldehyde, immersed for 3 hours in 15% sucrose, then overnight in 30% sucrose and finally embedded in Tissue-Tek O.C.T. compound (SAKURA), snap-frozen in liquid nitrogen and stored at −80°C. 8 μm sections were prepared by a cryostat (Leica CM1850), put on superfrost slides (R. Langenbrinck) and blocked with PBS containing 5% mouse serum and 5% goat serum. Staining was performed for 1h
at room temperature with a rabbit-anti-LCMV serum (own production) followed by AlexaFluor488-conjugated goat-anti-rabbit IgG Ab (Thermo Fisher). Images were acquired using the Axioplan2 imaging microscope with AxioCam MRm and Plan-NEOFLUAR 10x/0.30 objective and analyzed by AxioVision software (all from Zeiss).
Analysis of vascular permeability
Vascular permeability was assessed by Evans blue (EB) extravasation assay as described previously [5, 6] . In brief, mice were injected i.v. with 200 μL PBS containing 0.5% EB dye. After 15 min, mice were lethally anesthetized and transcardially perfused with 10 ml PBS. Liver and lungs were excised, weighed and incubated for 24 hours in 2 ml formamide at 56°C. The amount of extracted EB was determined by photometrical analysis at 620 nm using a standard curve.
Statistics
Statistical differences between two groups were determined using unpaired two-tailed t-test with Welch-correction or Mann-Whitney Test depending on whether data demonstrated Gaussian distribution or not. GraphPad InStat 3 software was used for determination of p-values. Differences at values of *p < 0.05, **p < 0.01 and ***p < 0.001 were considered to be significant.
